Comparative Risk of the Onset of Atrial Fibrillation after Icosapent Ethyl versus Omega-3 –Acid-Ethyl-Esters Adjuvant to Statins
View ORCID ProfileJyotirmoy Sarker, View ORCID ProfileMichael Kim, Samantha Patton, View ORCID ProfilePrzemysław B. Radwański, View ORCID ProfileMark A. Munger, View ORCID ProfileKibum Kim
doi: https://doi.org/10.1101/2024.09.16.24313779
Jyotirmoy Sarker
1Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago, Chicago, Illinois
M.Pharm., M.B.A.Michael Kim
1Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago, Chicago, Illinois
Pharm.D.Samantha Patton
2Department of Pharmacotherapy, University of Utah Health, Salt Lake City, Utah; 2Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, USA
Przemysław B. Radwański
3The Frick Center for Heart Failure and Arrhythmia, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, US
4Division of Pharmacology and Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, US
Pharm.D., Ph.D.Mark A. Munger
2Department of Pharmacotherapy, University of Utah Health, Salt Lake City, Utah; 2Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, USA
5Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah
Pharm.D.Kibum Kim
1Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago, Chicago, Illinois
PhD
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Posted September 17, 2024.
Comparative Risk of the Onset of Atrial Fibrillation after Icosapent Ethyl versus Omega-3 –Acid-Ethyl-Esters Adjuvant to Statins
Jyotirmoy Sarker, Michael Kim, Samantha Patton, Przemysław B. Radwański, Mark A. Munger, Kibum Kim
medRxiv 2024.09.16.24313779; doi: https://doi.org/10.1101/2024.09.16.24313779
Comparative Risk of the Onset of Atrial Fibrillation after Icosapent Ethyl versus Omega-3 –Acid-Ethyl-Esters Adjuvant to Statins
Jyotirmoy Sarker, Michael Kim, Samantha Patton, Przemysław B. Radwański, Mark A. Munger, Kibum Kim
medRxiv 2024.09.16.24313779; doi: https://doi.org/10.1101/2024.09.16.24313779
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2918)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12711)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4567)
- Geriatric Medicine (415)
- Health Economics (726)
- Health Informatics (2913)
- Health Policy (1068)
- Hematology (386)
- HIV/AIDS (922)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (467)
- Neurology (4335)
- Nursing (234)
- Nutrition (636)
- Oncology (2261)
- Ophthalmology (643)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (499)
- Pediatrics (1196)
- Primary Care Research (494)
- Public and Global Health (6916)
- Radiology and Imaging (1524)
- Respiratory Medicine (915)
- Rheumatology (436)
- Sports Medicine (383)
- Surgery (486)
- Toxicology (60)
- Transplantation (210)
- Urology (178)